| Income and other revenues | — | — | — |
| Income from financial royalty assets | 2,149.42a | 2,197.75a | 2,125.1a |
| Other royalty income and revenues | 114.15a | 156.8a | 112.12a |
| Total income and other revenues | 2,263.58a | 2,354.55a | 2,237.22a |
| Operating expense | — | — | — |
| Provision for changes in expected cash flows from financial royalty assets | -732.46a | -560.66a | -904.24a |
| Research and development funding expense | -2a | -52a | -177.11a |
| Amortization of intangible assets | | | -5.67a |
| General and administrative expenses | -236.67a | -249.75a | -227.3a |
| Financial royalty asset impairment | | | -615.83a |
| Total operating expense, net | -971.13a | -862.4a | -1,930.15a |
| Operating income | 1,292.44a | 1,492.15a | 307.07a |
| Other (income)/expense | — | — | — |
| Equity in (earnings)/losses of equity method investees | -29.61a | -28.88a | 8.97a |
| Interest expense | -225.51a | -187.19a | -187.96a |
| Losses/(gains) on derivative financial instruments | 6a | 2.29a | -96.61a |
| (Gains)/losses on equity securities | -39.55a | -87.14a | 33.44a |
| (Gains)/losses on available for sale debt securities | -154.91a | -230.84a | 6.82a |
| Interest income | -47.34a | -72.29a | -78.34a |
| Other non-operating expenses, net | 1.53a | 21.74a | 14.76a |
| Total other (income)/expense, net | -38.37a | -207.94a | 77a |
| Consolidated net income before tax | 1,330.81a | 1,700.09a | 230.06a |
| Income tax expense | | | |
| Consolidated net income | 1,330.81a | 1,700.09a | 230.06a |
| Net income attributable to non-controlling interests | 471.83a | 565.25a | 187.23a |
| Net income attributable to Royalty Pharma plc | 858.98a | 1,134.83a | 42.83a |